BPC-157 + TB-500: separate vials and blends
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
— mL · U-100
Syringe markings measure volume. They are not IU of the compound. Calculations do not account for handling losses or product stability.
— mL · U-100
Syringe markings measure volume. They are not IU of the compound. Calculations do not account for handling losses or product stability.
Reference notes
A separate-vial setup needs a separate concentration and volume calculation for each compound. A labelled blend instead uses its combined mass and component ratio.
The source describes a 4–6-week overlap with BPC-157 daily and TB-500 once or twice weekly; elsewhere it also says BPC-157 daily/EOD. These are source descriptions, not an MGMT protocol.
| Vial composition | Concentration | Volume | Units | Each component |
|---|---|---|---|---|
| 5 mg + 5 mg | 5 mg/mL | 0.1 mL | 10 | 250 mcg |
| 10 mg + 10 mg | 10 mg/mL | 0.1 mL | 10 | 500 mcg |
Source & content review 3 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source describes inconsistent BPC-157 frequency: daily/twice daily versus daily/EOD. No frequency was silently chosen.
- Some TB-500 source table targets exceed total vial content or the displayed syringe capacity.
Captured source values
{
"numericalFacts": [
"For the 1:1 blend, total target = component target × 2."
]
}